Beta bionics reports second quarter 2025 financial results and raises full year 2025 guidance

Irvine, calif., july 29, 2025 (globe newswire) -- beta bionics, inc. (nasdaq: bbnx), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended june 30, 2025 and raised its full year guidance for the year ending december 31, 2025.
BBNX Ratings Summary
BBNX Quant Ranking